Back to search

United Kingdom· GB-APID-22683211000001107

Amitiza 24microgram capsules

A lubiprostone product containing lubiprostone, registered in United Kingdom by Sucampo Pharma Europe Ltd. The same ATC class is registered in 4 of our 19 countries.

ATC A06AX03

Checked against NHS dm+d (United Kingdom) on

Informational only — not a medical device.

SOURCE REGISTER · GBNHS dm+d (United Kingdom)normalisedAmitiza 24microgram capsulesATCA06AX03REGISTER NO.GB-APID-2268321100000…PACKS LISTED2CHECKEDSeptember 13, 2026

Where it is registered

Lubiprostone is registered in 4 of 19 countries.

Countries holding a registration under ATC A06AX03 (lubiprostone), each read from that country’s own register.

  • This record: United Kingdom, from NHS dm+d (United Kingdom)
  • 2 of them publish a price we can compare per daily dose

Lubiprostone · ATC A06AX03

4 / 19 countries

  • Belgiumprice
  • Japan
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

NHS dm+d (United Kingdom)
Active substance
Lubiprostone
Manufacturer
Sucampo Pharma Europe Ltd
Country
United Kingdom (GB)
ATC code
A06AX03
ATC class
Lubiprostone
Reimbursed
Not published by this register
Source register
NHS dm+d (United Kingdom)
Last checked
September 13, 2026

Packs & prices · 2

  • gtin
    7640157441016
  • gtin
    7640157441511

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

2 interactions on record for lubiprostone.

Graded by severity as the source publishes them — 2 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Lubiprostone · interactions on record

2 records

  • 2 moderate

Most severe, free to view

  • IdelalisibL01EM01moderate
  • IdelalisibL01XX47moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Lubiprostone in 2 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lubiprostone products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/cd374784-d0d2-4998-90ee-e54c8fad375a
GET /v1/drugs/cd374784-d0d2-4998-90ee-e54c8fad375a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "apid": "22683211000001107",
  "desc": "Amitiza 24microgram capsules (Sucampo Pharma Europe Ltd)",
  "form": "Oral capsule",
  "vpid": "42296011000001107",
  "source": "dmd",
  "vtm_id": "776583003",
  "strength": "24 microgram",
  "substance": "Lubiprostone",
  "ingredient": "Lubiprostone",
  "supplier_code": "22684011000001100"
}

See everything about lubiprostone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.